Concepedia

Author

Coralie Poncet

European Organisation for Research and Treatment of CancerORCID

Also Known As

C Poncet, C. Poncet, Coralie Poncet, Gaetan MacGrogan, H.-H. Peter, Poncet, Coralie

118

Publications

2.3K

Citations

23

H-Index

23

Concepts

All Affiliations

European Organisation for Research and Treatment of CancerInstitut Jules BordetChampalimaud FoundationThe Netherlands Cancer InstituteBristol-Myers Squibb (France)
CP

About

Coralie Poncet is an author at European Organisation for Research and Treatment of Cancer specializing in oncology, radiation oncology, and breast cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

865

2

Health Sciences

5

5

484

3

Pathology

3

3

436

4

Biostatistics

1

1

336

5

Obstetrics

1

1

381

Coralie Poncet

×

27

Publications

1.8K

Citations

21

H-Index

YearCitations

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Fátima Cardoso, John M.S. Bartlett, Leen Slaets,

Annals of Oncology

2017

381

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart, Laura van ‘t Veer, Coralie Poncet,

The Lancet Oncology

2021

336

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial

Sanne A. L. Bartels, Mila Donker, Coralie Poncet,

Journal of Clinical Oncology

2022

322

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

Marion van Mackelenbergh, Sibylle Loibl, Michael Untch,

Journal of Clinical Oncology

2023

90

MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.

Fátima Cardoso, Laura van ‘t Veer, Coralie Poncet,

Journal of Clinical Oncology

2020

63

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

Michael Schiff, M. Keiserman, C. Codding,

Annals of the Rheumatic Diseases

2011

55

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

Pierre Squifflet, Everardo D. Saad, Sibylle Loibl,

Journal of Clinical Oncology

2023

53

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

H. Nüßlein, Rieke Alten, Mauro Galeazzi,

BMC Musculoskeletal Disorders

2014

49

Obesity-associated changes in molecular biology of primary breast cancer

Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens,

Nature Communications

2023

48

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study

Rieke Alten, H. Nüßlein, Xavier Mariette,

RMD Open

2017

43

Page 1